Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent, Inc. insider-related trust plans stock sale under Rule 144. A holder of Nuvalent Class A common stock filed notice to sell 5,850 shares through J.P. Morgan Securities LLC, with an aggregate market value of 588,990, on or around 02/17/2026 on Nasdaq.
The securities were originally acquired as founder shares from the issuer on 02/17/2017. The filing also lists recent sales by the same trust, including 5,850 Class A shares sold on 11/24/2025 for gross proceeds of 639,807 and additional smaller transactions over the following months.
Nuvalent, Inc. received an amended Schedule 13G/A showing that investment entities affiliated with Deerfield report significant beneficial ownership of its Class A common stock. Deerfield Management Company, L.P. and James E. Flynn each report beneficial ownership of 22,852,280 shares, or 24.21% of the Class A shares outstanding.
This position includes 17,248,450 existing Class A shares, 5,435,254 Class A shares issuable upon conversion of Class B shares, and 168,576 Class A shares underlying options and restricted stock units held by Nuvalent employees for Deerfield’s benefit. Several related Deerfield funds individually report 11.56% or 0.91% stakes.
The Class B shares are subject to an Ownership Cap that generally limits conversions so that the holder and its affiliates do not exceed 4.9% of Nuvalent’s outstanding Class A common stock upon conversion.
Nuvalent, Inc.’s Chief Development Officer, Darlene Noci, reported an options exercise and related share sales. On January 29, 2026, she exercised 5,500 stock options at $27.85 per share, receiving the same number of Class A common shares.
That same day she sold portions of Class A common stock in several trades: 189 shares at $100.95, 3,429 shares at $101.8, 1,819 shares at $102.67, and 63 shares at $103.39, with prices reported as weighted averages. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
After the reported transactions, Noci directly held 58,117 shares of Class A common stock and 108,829 stock options. The option underlying the 5,500-share exercise vests in equal monthly installments over four years following January 6, 2023, subject to continued service.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported option exercises and share sales under a pre-arranged trading plan. On January 21, 2026 she exercised 700 stock options at an exercise price of $27.85 per share and sold 700 shares of Class A common stock at a weighted average price of $109.84 per share, leaving 59,634 shares owned directly. On January 22, 2026 she exercised an additional 14,300 options at $27.85 per share and sold 14,300 shares at a weighted average price of $110.16 per share, again leaving 59,634 shares owned directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024, and the underlying options vest in equal monthly installments over four years following January 6, 2023, subject to continued service.
Nuvalent insider Deborah Miller has filed a Form 144 notice to sell up to 21,000 shares of Nuvalent common stock. The shares are to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of 01/22/2026. The filing notes that 67,271,461 common shares were outstanding.
The 21,000 shares were acquired on 01/22/2026 via a cash exercise of stock options from the issuer. The notice also lists recent sales of Nuvalent common stock over the past three months, including 24,200 shares sold on 11/17/2025 and 21,800 shares sold on 10/30/2025, some under Rule 10b5-1 trading arrangements. By signing, the seller represents that she is not aware of undisclosed material adverse information about the company.
Nuvalent, Inc. furnished an update indicating that it preliminarily estimates having approximately $1.4 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is described as a preliminary, unaudited estimate as of January 12, 2026 and may change once year-end financial closing procedures are completed, so it does not provide a full picture of the company’s financial condition at that date. The estimate was disclosed via a press release attached as Exhibit 99.1, which is being furnished rather than filed, and the company notes that related statements are forward-looking and subject to risks outlined in its prior SEC reports.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported a mix of stock sales and new equity awards. On January 5–6, 2026, he sold multiple blocks of Nuvalent Class A Common Stock in open-market transactions, including 513 shares at a weighted average price of $96.06, 660 shares at $96.85, 1,137 shares at $97.96, 186 shares at $98.52, 1,106 shares at $96.75, 1,369 shares at $97.33 and 189 shares at $98.40.
According to the footnotes, these sales were made under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations on vesting equity awards. On January 7, 2026, Pelish acquired 17,500 shares of Class A Common Stock for $0.00 pursuant to restricted stock units that vest in three equal annual installments after January 7, 2026, and received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported several sales and equity awards involving the company’s Class A Common Stock. On January 5 and 6, 2026, she sold multiple small blocks of shares under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations upon vesting of earlier equity awards. Reported weighted average sale prices include $96.06, $96.85, $97.96 and $98.52 per share.
On January 7, 2026, Noci reported an acquisition of 17,500 Class A shares for $0.00 per share, representing restricted stock units that vest in three equal annual installments following that date, subject to continued service. She also received a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026. Following these transactions, she directly owned 58,117 Class A shares and 17,500 stock options.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported multiple transactions in the company’s Class A Common Stock. On January 5–6, 2026, she sold several small blocks of shares at weighted average prices generally ranging from about $95.34 to $99.10 per share, with the filing noting these sales were made under a durable Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding obligations on previously granted equity awards.
On January 7, 2026, she received 17,500 restricted stock units (RSUs), each representing one share of Class A Common Stock, which vest in three equal annual installments following that date, and a stock option for 17,500 shares at an exercise price of $106.82 that vests in equal monthly installments over four years. After these transactions, she directly beneficially owned 59,634 shares of Class A Common Stock and 17,500 stock options.
Nuvalent, Inc. Chief Medical Officer Christopher Durant Turner reported multiple sales of Class A common stock on January 5–6, 2026, at weighted average prices generally in the $96–$99 range. The filing notes these sales were executed under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to cover tax withholding on previously vested equity awards.
On January 7, 2026, he reported the acquisition of 17,500 restricted stock units (RSUs), each representing one share of Class A common stock, which vest in three equal annual installments following January 7, 2026, subject to continued service. He also received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years following January 7, 2026.